Overcoming Challenges in Technology Transfer: Insights from Roberto Formisano

Current developments in technology transfer to a Contract Development and Manufacturing Organization (CDMO)

During a recent video interview, Roberto Formisano, Process Transfer Senior Manager at AGC Biologics, discussed the challenges associated with technology transfer in the cell and gene therapy industry. He provided valuable insights on the intricacies of technology transfer, both from development to GMP manufacturing and from a customer to a contract development and manufacturing organization (CDMO).

One of the key challenges that Roberto highlighted is the critical timelines that are essential for technology transfer. Balancing the number of batches required to generate sufficient quality data while adhering to these timelines can be challenging in the industry. However, Roberto’s predictions on technology and manufacturing trends that are expected to shape the cell and gene therapy industry by 2024 provide valuable insights into the future direction of the industry.

Roberto Formisano had a conversation with EPR editor Caroline Peachey at Terrapin’s Advanced Therapies conference in London on 19 March. The interview sheds light on the complexities of technology transfer and offers valuable insights into the industry’s challenges and opportunities.

In conclusion, technology transfer is an essential aspect of cell and gene therapy development, but it comes with its own set of challenges. Roberto Formisano’s insights provide valuable perspectives on how these challenges can be overcome and what lies ahead for the industry.

Leave a Reply